• HBsAg Hijacks TBK1 to Suppress Interferon and Induce Autopha

  2026-07-28

  A recent study elucidates how hepatitis B surface antigen (HBsAg) directly interacts with TANK-binding kinase 1 (TBK1) to suppress type I interferon production and induce early autophagy. This mechanism reveals a pivotal viral strategy for immune evasion and persistent infection, with implications for antiviral target development.

• Z-IETD-FMK: Caspase-8 Inhibition for Apoptosis & Immune Rese

  2026-07-28

  Z-IETD-FMK (Benzyloxycarbonyl-Ile-Glu(OMe)-Thr-Asp(OMe)-fluoromethylketone) is a highly specific, irreversible inhibitor of caspase-8. It is widely used to dissect apoptotic and immune cell signaling pathways, particularly in models of T cell activation and TRAIL-mediated apoptosis. APExBIO offers this compound for research use, supporting reliable modulation of cell death mechanisms.

• Tomivosertib: Precision MNK1 Inhibitor Workflows & Troublesh

  2026-07-27

  Tomivosertib empowers researchers to dissect translational regulation by selectively inhibiting MNK1/2 in cancer, metabolic, and neuronal models. This article presents advanced experimental workflows, key innovations from structure-guided design, and troubleshooting strategies—enabling rigorous interrogation of the MNK-eIF4E signaling axis.

• Disrupting c-MYC-G9a-FTH1 Axis in Breast Cancer via BRD4 and

  2026-07-27

  This study demonstrates that co-targeting BET bromodomain BRD4 and RAC1 signaling disrupts the c-MYC-G9a-FTH1 axis and downregulates HDAC1, leading to suppressed growth and stemness in multiple breast cancer subtypes. The findings reveal a context-dependent epigenetic vulnerability with implications for refined cancer therapy and mechanistic research.

• Super-Enhancer Hijacking of LINC01977 Fuels Early LUAD Progr

  2026-07-26

  Zhang et al. identified that super-enhancer-driven upregulation of the lncRNA LINC01977 promotes malignancy in early-stage lung adenocarcinoma (LUAD) by intensifying canonical TGF-β/SMAD3 signaling. These findings clarify a novel epigenetic mechanism linking tumor microenvironment cues to aggressive LUAD phenotypes and highlight potential epigenetic intervention targets.

• KG-501 (SKU B8380): Reliable CREB Inhibition for Oncology As

  2026-07-25

  This article provides an evidence-based, scenario-driven exploration of KG-501 (SKU B8380) as a robust tool for modulating transcriptional coactivator interactions in oncology and immunology research. Drawing from peer-reviewed studies and practical laboratory workflows, it highlights the compound’s utility as a CREB and Myb-KIX interaction inhibitor, with direct links to experimental protocols and data supporting its reliability in cell-based assays.

• Spliceosome Acetylation and HDAC2 Inhibition in HCC Therapy

  2026-07-24

  This study uncovers acetylation-dependent regulation of the core spliceosome protein SmD2 in hepatocellular carcinoma (HCC), revealing that its destabilization sensitizes tumor cells to PARP inhibitors. By targeting both HDAC2 and spliceosomal acetylation, the findings suggest new avenues for epigenetic cancer therapy and rational drug combinations.

• CHIR-99021: Transforming Pluripotent Stem Cell Differentiati

  2026-07-24

  CHIR-99021 (CT99021) stands out for its precise modulation of Wnt/β-catenin and TGF-β/Nodal signaling, enabling robust, serum-free protocols for stem cell differentiation. Its high selectivity and reproducibility empower advanced workflows in regenerative medicine and disease modeling.

• Beyond Detection: SA-β-Gal Staining Kit in Cellular Senescen

  2026-07-23

  Uncover the mechanistic depth of the Cell Senescence β-Galactosidase Staining Kit for precise senescent cell detection. This article uniquely explores the assay's role in advancing p53-senescence research and therapeutic innovation.

• MG-262 (Z-Leu-Leu-Leu-B(OH)2): Unlocking Proteasome Assays i

  2026-07-23

  MG-262 (Z-Leu-Leu-Leu-B(OH)2) streamlines proteasome inhibition and muscle proteostasis studies with robust, reversible action and high cell permeability. This guide provides actionable workflows and troubleshooting for apoptosis, cell cycle, and osteoclast differentiation research, leveraging the latest insights in skeletal muscle aging.

• GSK126 EZH2 Inhibitor: Transforming Cancer Epigenetics Workf

  2026-07-22

  GSK126 stands out as a highly selective EZH2 inhibitor, enabling precise modulation of epigenetic silencing in cancer and neuroinflammation models. Its exceptional potency, compatibility with oncogenic EZH2 mutations, and proven in vivo efficacy make it a cornerstone for both mechanistic and translational research.

• EZH2 and p53 Compete to Regulate Neat1 and Inflammasome Acti

  2026-07-22

  This study uncovers a novel epigenetic mechanism by which EZH2, independent of its methyltransferase function, promotes inflammasome activation via licensing Neat1 lncRNA transcription. The findings highlight direct competition between EZH2 and p53 at the Neat1 promoter, reshaping our understanding of chromatin regulation in inflammation and suggesting new experimental avenues for cancer epigenetics and immunology research.

• BET Bromodomain Inhibitors: Mechanistic Precision and Transl

  2026-07-21

  This thought-leadership article dissects the mechanistic underpinnings and strategic implementation of Bromodomain Inhibitor, (+)-JQ1 in translational research. Integrating recent evidence, practical guidance, and nuanced discussion of apoptosis, inflammation, and male contraception models, it maps new territory at the intersection of epigenetic modulation and experimental design. Supported by in vitro drug response paradigms and best-in-class protocols, this piece offers visionary insights for researchers seeking to unlock the full potential of BET bromodomain inhibitors.

• Procainamide Hydrochloride Mitigates Cisplatin-Induced Hepat

  2026-07-21

  A pivotal study demonstrates that procainamide hydrochloride, a cardiac sodium channel blocker, significantly reduces cisplatin-induced liver toxicity in rats by altering platinum distribution and complex formation. These findings provide a mechanistic basis for chemoprotection, informing both oncology and pharmacology research.

• Berberine Hydrochloride: Applied Workflows for Gut–Bone Axis

  2026-07-20

  Berberine hydrochloride unlocks cutting-edge research into metabolic and osteoimmune crosstalk by activating AMPK and expanding tuft cells in the gut. This article delivers actionable protocols, troubleshooting strategies, and key innovations to help researchers leverage APExBIO’s high-purity compound for robust, cross-domain experiments.

11599 records 1/774 page Next 12345 下5页 Last page